Correlation between the CD4+CD25 high regulatory T cells and the outcome of chemotherapy in advanced esophageal carcinoma

Hepato-Gastroenterology

Volumn 60, Issue 124, 2013, Pages 704-708

  Wang, Gang ^a   Sun, Yubei ^a   Ji, Chushu ^a   He, Yifu ^a   Hu, Changlu ^a   Jiang, Fengshou ^a   Chen, Manping ^a   Duan, Qiaohong ^b   Fan, Pingsheng ^b   Hu, Bing ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b Anhui Tumor Hospital   (China)

Author keywords

Advanced esophageal carcinoma; CD4+ cD25+ regulatory T cells; Chemotherapy; Survival time

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; PLATINUM;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONSTIPATION; DOWN REGULATION; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; KIDNEY INJURY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA AND VOMITING; PHLEBITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STOMATITIS; SURVIVAL TIME; TREATMENT OUTCOME; ESOPHAGUS TUMOR; FLOW CYTOMETRY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84879560256     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12953     Document Type: Article

References (23)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12):2893-2917.
2. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003; 349(23):2241-2252. (Pubitemid 37485141)
3. Sjoquist KM, Burmeister BH, Smithers BM, et al.: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12(7):681-692.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4):225-249.
5. O'Sullivan GC, Corbett AR, Shanahan F, Collins JK: Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. J Immunol 1996; 157(10):4717-4720. (Pubitemid 126449396)
6. O'Mahony AM, O'Sullivan GC, O'Connell J, Cotter TG, Collins JK: An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 1993; 151(9):4847-4856. (Pubitemid 23318538)
7. Sakaguchi S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101(5):455-458.
8. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155(3):1151-1164.
9. Yamaguchi T, Sakaguchi S: Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006; 16(2):115-123. (Pubitemid 43172060)
10. Somasundaram R, Jacob L, Swoboda R, et al.: Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 2002; 62(18):5267-5272. (Pubitemid 35024601)
11. Woo EY, Chu CS, Goletz TJ, et al.: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61(12):4766-4772. (Pubitemid 32691889)
12. Liyanage UK, Moore TT, Joo HG, et al.: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169(5):2756-2761. (Pubitemid 34921025)
13. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65(6):2457-2464. (Pubitemid 40490158)
14. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9(12):4404-4408. (Pubitemid 37248397)
15. Xu T, Duan Q, Wang G, Hu B: CD4 + CD25high regulatory T cell numbers and FOXP3 mRNA expression in patients with advanced esophageal cancer before and after chemotherapy. Cell Biochem Biophys 2011; 61(2):389-392.
16. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E: Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15(7):1042-1047. (Pubitemid 39089780)
17. Muggia FM, Carter SK, Macdonald JS: The Cancer Therapy Evaluation Program of the National Cancer Institute. Semin Oncol 1981; 8(4):394-402. (Pubitemid 12180591)
18. Cheng M, Zhang J, Jiang W, Chen Y, Tian Z: Natural killer cell lines in tumor immunotherapy. Front Med 2012; 6(1):56-66.
19. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356(9232):802-807.
20. Powrie F, Read S, Mottet C, Uhlig H, Maloy K: Control of immune pathology by regulatory T cells. Novartis Found Symp 2003; 252:92-98; discussion 98-105, 106-114.
21. Mason D, Powrie F: Control of immune pathology by regulatory T cells. Curr Opin Immunol 1998; 10(6):649-655. (Pubitemid 28558579)
22. Nozoe T, Saeki H, Ohga T, Sugimachi K: Clinicopathologic characteristics of esophageal squamous cell carcinoma in younger patients. Ann Thorac Surg 2001; 72(6):1914-1917. (Pubitemid 34001441)
23. van Nistelrooij AM, Andrinopoulou ER, van Lanschot JJ, Tilanus HW, Wijnhoven BP: Influence of young age on outcome after esophagectomy for cancer. World J Surg 2012; 36(11):2612-2621.